Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic disorders characterized by malignant transformation and proliferation of lymphoid progenitor cells in bone marrow, periphery blood, and extramedullary sites [1].Survival of ALL has increased as a result of advances in management efficacy as well as risk stratification to determine the most appropriate treatment regimen. Objective Background
